In CHOL, we revealed that XPO1 inhibitor KPT‐330 could trigger the nuclear accumulation of the p53 protein and in this way significantly disrupted the proliferation of cholangiocarcinoma cells. Here, TP53 is linked to cholangiocarcinoma.